3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
Key PointsEven if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year.
Key PointsEven if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year.